Xencor (XNCR) investor relations material

Executive summary

• Focused on developing engineered antibody therapeutics for cancer and autoimmune diseases, with a portfolio of clinical and partnered programs leveraging XmAb technology platforms.

• Multiple clinical milestones achieved, including Phase 1 and 2 studies across oncology and autoimmune indications; seven clinical studies are ongoing.

• XmAb819 ccRCC expansion data to be presented at ESMO 2026; new sub-studies and combination trials initiated or planned.

• XmAb942 enrollment on track for XENITH-UC Phase 2b study; primary endpoint expected in 2H27.

• Strategic portfolio management includes advancing, partnering, or discontinuing programs based on data and priorities.

Financial highlights

• Total revenue for Q2 2026 was $51.2M, up $7.6M year-over-year, driven by milestone and royalty revenue.

• Net loss for Q2 2026 was $21.7M ($0.29/share), improved from $30.8M ($0.41/share) in Q2 2025; six-month net loss was $150.6M ($1.99/share) vs. $79.2M ($1.07/share) prior year.

• R&D expenses for Q2 2026: $71.9M, up from $61.7M year-over-year, reflecting increased pipeline investment.

• Cash, cash equivalents, and marketable debt securities totaled $486.4M as of June 30, 2026, down from $610.8M at year-end 2025.

• Other income, net, increased to $15.1M in Q2 2026, mainly due to unrealized gains on equity securities.

Outlook and guidance

• Current financial resources are expected to fund operations through at least the next twelve months and potentially through 2028, depending on milestone receipts and operating plans.

• Expects to end 2026 with $420M–$440M in cash and equivalents.

• Ongoing and planned clinical trials and potential milestone payments from partners are expected to drive future revenue.

• Anticipates multiple clinical data readouts and regulatory milestones in 2027 and beyond.